Major surgery within  days before the start of trial treatment (excluding prior diagnostic biopsy); or use of any investigational drug within  days before the start of trial treatment.
Systemic therapy with immunosuppressive agents within  days before the start of treatment; or use of any investigational drug within  days before the start of trial treatment.
Systemic therapy with immunosuppressive agents within  days before the start of treatment; or use of any investigational drug within  days before the start of trial treatment.
Concurrent use of other investigational drugs or treatment in another clinical trial with a non-FDA-approved medication within the past  weeks before start of therapy
Treatment with other investigational agents including chemotherapy, immunotherapy, or radiation therapy within a month prior to the start of this clinical trial
Concurrent anticancer treatment within  days before the start of trial treatment (e.g., cytoreductive therapy, radiotherapy [with the exception of palliative bone directed radiotherapy], immune therapy, or cytokine therapy except for erythropoietin); major surgery within  days before the start of trial treatment (excluding prior diagnostic biopsy); concurrent systemic therapy with immunosuppressive agents within  days before the start of trial treatment; use of hormonal agents within  days before the start of trial treatment; or use of any investigational drug within  days before the start of trial treatment; Note: subjects receiving bisphosphonate or denosumab are eligible provided treatment was initiated at least  days before the first dose of avelumab
Treatment with other investigational drugs or treatment in another clinical trial within the past  weeks before start of therapy or concomitantly with the trial
Concurrent anticancer treatment within  days before the start of trial treatment
Use of any investigational drug within  weeks before start of trial treatment or concomitantly with this trial.
Systemic therapy with immunosuppressive agents within  days before the start of trial treatment; or use of any investigational drug within  days before the start of trial treatment
Treatment with other investigational drugs or treatment in another clinical trial within the past  weeks before start of therapy or concomitantly with the trial
Concurrent anticancer treatment (e.g., cytoreductive therapy, radiotherapy except for palliative bone-directed radiotherapy, immune therapy, or cytokine therapy except for erythropoietin) within  days before start of trial treatment; major surgery within  days before start of trial treatment (excluding prior diagnostic biopsy); use of hormonal agents within  days before start of trial treatment, except for subjects with castration-resistant prostate cancer (CRPC), who may remain on treatment with luteinizing hormone-releasing hormone agonists or antagonists; or use of any investigational drug within  days before start of trial treatment. Note: Small molecule or antibody targeted therapy is permissible < days from start of trial treatment.
Chemotherapy within  days of the start of this trial
Treatment with other investigational drugs or treatment in another clinical trial within the past  weeks before start of therapy or concomitantly with the trial
Administration of other investigational agents for the treatment of AML/MDS within  days (or  times the terminal half-life of the investigational treatment whichever is longer) of the start of this trial and throughout the duration of this trial
Treatment with other investigational agents, chemotherapy, or immunotherapy within  days of the start of this trial and throughout the duration of this trial
Treatment with another investigational drug within the past four weeks before start of therapy or concomitantly with this trial.
Treatment with other investigational drugs or treatment in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial
Treatment with a investigational drug within  days before Day  of trial treatment.
